Clinical Study on the Therapeutic Role of Midodrine in Non azotemic Cirrhotic Patients with Tense Ascites: A Double-Blind, Placebo-Controlled, Randomized Trial

Citation:
Kassem, M. A., A. Ali, S. Farid, and M. Amin, "Clinical Study on the Therapeutic Role of Midodrine in Non azotemic Cirrhotic Patients with Tense Ascites: A Double-Blind, Placebo-Controlled, Randomized Trial", Hepato-Gastroenterology, vol. 61, issue 1915, pp. 1915-1924, 2014.

Abstract:

ABSTRACT
Background: Midodrine is an α-agonist prodrug of des¬glymidodrine used for the management of hypotension. Midodrine has demonstrated usefulness in hepatore¬nal syndrome. Objective: The objective of the present work was to study the role of midodrine in patients with non-azotemic cirrhosis with tense ascites. Meth¬ods: This prospective randomized double blind place¬bo-controlled study was conducted on 67 non azotemic inpatients with liver cirrhosis and tense ascites (52 men and 15 women; age range, 45-72). One patient declined to participate in the study, 33 patients were randomly assigned to take midodrine hydrochloride, and 33 pa¬tients were randomly assigned to take placebo. Out of 67 enrolled patients, 60 patients (30: in midodrine group; 30: in placebo group) completed the study and 6 patients lost to follow up. Patients were assessed for patients’ characteristics, history of tapping their ascitic fluid, laboratory values, and Doppler parameters before and after the study. Average 24-h urine volume was as¬sessed before and after the start of the study. Results: significant reduction in body weight and abdominal girth was observed after 2 weeks of midodrine therapy. Conclusion: Midodrine appeared to be effective in low¬ering body weights and abdominal girths of non azo¬temic cirrhotic patients with tense ascites.